Please assess the completion status of the following clinical trial:

Trial Title: Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of CPVT, based on:~   A. reproducible polymorphic or bidirectional ventricular tachycardia with exercise OR B. Ventricular ectopy on exercise test with RYR2 or CASQ2 mutation~2. Functioning ICD in place~3. On stable dose of standard therapy defined as the maximal tolerated dose of beta-blocker and may include a calcium channel blocker~Patients on flecainide or mexiletine are also eligible for enrollment after a 1 week washout period during which flecainide or mexiletine is discontinued, and standard therapy alone is used.~Exclusion Criteria:~1. Females who are pregnant or plan to be pregnant during the study period~2. Children \< 5 years of age~3. Patients unable to perform treadmill exercise~4. Patients with significant structural heart disease~5. Patients with features consistent with Andersen-Tawil syndrome A. Periodic paralysis or unexplained weakness B. Dysmorphic facies C. Known KCNJ2 mutation~6. Patients with known hypersensitivity to flecainide~7. Patients on amiodarone~8. Patients not expected to comply with follow-up

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Flecainide then placebo (Type: OTHER): In this crossover study, half of the subjects will be randomized to flecainide plus standard therapy with beta-blockers first, then crossover to placebo plus standard therapy with beta-blockers.
- Placebo then flecainide (Type: OTHER): In this crossover study, half of the subjects will be randomized to placebo plus standard therapy with beta-blockers first, then crossover to flecainide plus standard therapy with beta-blockers.

Based on this trial design, predict the completion outcome and termination type (if applicable).